Navigation Links
FDA approves knee-injury device for humans
Date:10/2/2007

COLUMBIA, Mo. A new knee-surgery device investigated by University of Missouri-Columbia researchers that will help to repair meniscus tears, which were previously defined as irreparable, has been approved by the FDA for use in humans.

Previous treatment options forced surgeons to completely remove the damaged portion of the meniscus. Typically the removal of the meniscus leads to painful, debilitating arthritis in the knee. Herb Schwartz, president and CEO of Schwartz Biomedical, LLC, and James Cook, MU professor of veterinary medicine and surgery and William C. Allen Endowed Scholar for Orthopedic Research in MUs College of Veterinary Medicine, developed the BioDuct Meniscal Fixation Device. Schwartz and Cook believe that patients with meniscus tears will now be able to have their meniscus saved along with long-term knee function.

In the past, when faced with meniscus injuries, surgeons were often forced to completely remove the torn meniscal cartilage, leaving a deficient knee that was doomed to develop arthritis, Cook said. With the BioDuct Meniscal Fixation Device, surgeons will be able to repair torn menisci and induce healing. People with meniscus injuries now have a better future ahead.

The meniscus, a padding tissue that provides shock absorption and joint stability in the knee, is crucial for normal knee function. Surgeries for meniscus tears are common with approximately one million occurring in the United States each year. When meniscus function is deficient, bone rubs on bone and arthritis is likely to develop and progress. Because two-thirds of the meniscus is avascular (lacks a blood supply), a tear in that region will not repair itself. This new device will transport blood and cells from the vascular portion of the knee to the avascular portion of the meniscus. Supplied with blood and cells for healing, the previously untreatable meniscal tear now has the potential for allowing the knee joint to be saved.

Cooks research team performed the BioDuct surgery on 25 dogs that had worst-case scenario meniscal tears. With the BioDuct Meniscal Fixation Device, the meniscus in the dogs knees had complete or partial repair after a few weeks in all cases.

Currently, there are no other devices that can provide improved fixation over time, Schwartz said. Therefore, the BioDuct device is set apart from the rest of the field.

In his research, Cook found that the device will significantly improve healing of avascular meniscal tears both biologically and biomechanically, which should lessen the long-term effects of meniscus injuries, including osteoarthritis. Cooks recent findings were published in the American Journal of Sports Medicine.

The BioDuct device could impact the industry by improving repairs of the meniscus to such an extent that fewer patients develop arthritis that results from removing the meniscal tissue, Schwartz said. Thus, with fewer patients developing arthritis, the result could be fewer total joint replacements or at least delaying the need for a total joint replacement.


'/>"/>

Contact: Christian Basi
BasiC@missouri.edu
573-882-4430
University of Missouri-Columbia
Source:Eurekalert

Related medicine news :

1. FDA approves Phase 0 trial which tests experimental drugs on humans
2. FDA Approves Contraceptive Ring
3. FDA approves new device to treat womens bleeding disorder
4. FDA Approves New HIV Drug, Viread
5. FDA Approves Birth Control Skin Patch
6. FDA approves surgical gel
7. FDA Approves New Arthritis Drug, Bextra
8. FDA Approves Elidel Cream for Eczema
9. FDA approves drug for rare liver disease
10. FDA approves first pocket-sized EKG machine
11. FDA Approves New Anti-Clotting Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... Montclair, NJ (PRWEB) , ... March 23, 2017 ... ... the Renaissance Oklahoma City Convention Center at 10 North Broadway Avenue, will be ... 6.0 hours of relevant, practical instruction in the management of chronic pain. , ...
(Date:3/23/2017)... New Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The ... to the modular industry or whose acts have had a significant impact on the careers ... of Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits ... an innovative mobile app and centralized benefits dashboard solving one of the top ... from multiple locations. For the first time, employees can access up-to-date information and ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Valve Devices Market: Analysis By Procedure, Replacement Procedure By Technique, Repair ... their offering. ... Global Heart Valve Devices Market is forecasted to grow at a ... heart valve devices is driven by rising aging population, growth in ...
(Date:3/23/2017)... and INDIANAPOLIS , March ... LLY ) and the William Sansum Diabetes Center ... of Latino people affected by diabetes through enhanced research, ... of diabetes and cardiovascular disease bears a disproportionate weight ... ," said David Kerr , M.D., FRCPE, ...
(Date:3/23/2017)... , March 23, 2017 ... and Healthcare disease pipeline guide Primary Hyperoxaluria - ... the Primary Hyperoxaluria (Genito Urinary System And Sex ... rare condition characterized by recurrent kidney and bladder ... substance called oxalate. Symptoms include blood in the ...
Breaking Medicine Technology: